Project Grant DP2AI200953
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $448K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Arkansas for Medical Sciences $249,856 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate neutrophil inflammasome mechanisms in host defense and inflammatory responses. The research examines how neutrophils regulate pyroptosis—a form of lytic cell death triggered by inflammasomes—during bacterial infections and inflammatory conditions including sepsis and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $861,088 on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a novel monoclonal antibody targeting enampt (extracellular nicotinamide phosphoribosyl transferase) to reduce antimicrobial resistance following hospital-acquired and ventilator-associated bacterial pneumonia. The research will employ preclinical models of pneumonia caused by...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $199,059 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study competitive microbial interactions driving pathogen adaptation during biofilm-associated infections. The research addresses polymicrobial chronic wound infections, which are predicted to affect 2 percent of the U.S. population and cost the healthcare system up to $97...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $512,842 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how capsule O-acetyltransferases modulate pneumococcal fitness and contribute to bacterial virulence. The research focuses on characterizing the function of capsule polysaccharide O-acetyltransferase enzyme families in Streptococcus pneumoniae and their role in coordinating with...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $427,625 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing R21AI200336) to investigate the structure, biosynthesis, and pathogenic role of a previously unknown glycan receptor found on Acinetobacter baumannii and to characterize the molecular interaction between a broad host-range bacteriophage (STAB3) and that receptor. A. baumannii is a...
- The National Institute of Allergy and Infectious Diseases awarded University of New Haven, Incorporated $126,351 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop machine learning approaches for analyzing microbiome dynamics in ventilator-associated pneumonia. The project addresses VAP diagnostic delays and poor sensitivity in current clinical methods by developing interpretable machine learning models that integrate 16S rRNA sequencing...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...